Oncotarget · 2018 · 23 citations · 34 references
Life SciencesHematologyImmunologyCancer ImmunologyImmunotherapyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsImmune Checkpoint RegulationT Cell BiologyAntigen Presenting CellsAntigen Specificity DeterminationProgrammed Cell Death Protein 1 (Pd-1) PathwayProgrammed Death-ligand 1 TargetingT Cell Checkpoint InhibitionT Cell Functional AssaysT Cell-based ImmunotherapyT-cell Responses To Tumor Antigens
// Maarten Versteven 1, * , Johan M.J. Van den Bergh 1, * , Katrijn Broos 2, * , Fumihiro Fujiki 3, * , Diana Campillo-Davo 1 , Hans De Reu 1 , Soyoko Morimoto 4 , Quentin Lecocq 2 , Marleen Keyaerts 5, 6 , Zwi Berneman 1, 7, 8 , Haruo Sugiyama 3 , Viggo F.I. Van Tendeloo 1 , Karine Breckpot 2 and Eva Lion 1, 8 1 Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium 2 Laboratory for Molecular and Cellular Therapy, Vrije Universiteit Brussel, Brussels, Belgium 3 Department of Cancer Immunology, Osaka University Graduate School of Medicine, Osaka, Japan 4 Department of Cancer Immunotherapy, Osaka University Graduate School of Medicine, Osaka, Japan 5 In Vivo Cellular and Molecular Imaging Laboratory, Vrije Universiteit Brussel, Brussels, Belgium 6 Nuclear Medicine Department, UZ Brussel, Brussels, Belgium 7 Division of Hematology, University Hospital Antwerp, Antwerp, Belgium 8 Center for Cell Therapy and Regenerative Medicine, University Hospital Antwerp, Antwerp, Belgium * These authors contributed equally to this work Correspondence to: Maarten Versteven, email: maarten.versteven@uantwerpen.be Keywords: PD-1/PD-L1 immune checkpoint pathway; antigen-specific; bioassay; flow cytometry; immune checkpoint inhibition Received: January 16, 2018 Accepted: May 24, 2018 Published: June 12, 2018 ABSTRACT Blockade of programmed cell death protein 1 (PD-1) immune checkpoint receptor signaling is an established standard treatment for many types of cancer and indications are expanding. Successful clinical trials using monoclonal antibodies targeting PD-1 signaling have boosted preclinical research, encouraging development of novel therapeutics. Standardized assays to evaluate their bioactivity, however, remain restricted. The robust bioassays available all lack antigen-specificity. Here, we developed an antigen-specific, short-term and high-throughput T cell assay with versatile readout possibilities. A genetically modified T cell receptor (TCR)-deficient T cell line was stably transduced with PD-1. Transfection with messenger RNA encoding a TCR of interest and subsequent overnight stimulation with antigen-presenting cells, results in eGFP-positive and granzyme B-producing T cells for single cell or bulk analysis. Control antigen-presenting cells induced reproducible high antigen-specific eGFP and granzyme B expression. Upon PD-1 interaction, ligand-positive antigen-presenting immune or tumor cells elicited significantly lower eGFP and granzyme B expression, which could be restored by anti-PD-(L)1 blocking antibodies. This convenient cell-based assay shows a valuable tool for translational and clinical research on antigen-specific checkpoint-targeted therapy approaches.
34
Tadashi Yokosuka, Masako Takamatsu, Wakana Kobayashi-Imanishi et al. · The Journal of Experimental Medicine · 2012 · 1.2K citations · Full text
Viggo Van Tendeloo, Peter Ponsaerts, Filip Lardon et al. · Blood · 2001 · 458 citations · Full text